<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00432913</url>
  </required_header>
  <id_info>
    <org_study_id>EPA/POL/02</org_study_id>
    <nct_id>NCT00432913</nct_id>
  </id_info>
  <brief_title>Effect of 2 Doses of EPA on Apoptosis and Cell Proliferation on Colon Mucosa</brief_title>
  <official_title>The Effect of Two Dose Levels of Eicosapentaenoic Acid (EPA) on Apoptosis and Cell Proliferation in the Colonic Mucosa of Patients With a History of Colonic Polyps.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>S.L.A. Pharma AG</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>S.L.A. Pharma AG</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to determine the effect of two doses purified EPA (an omega-3&#xD;
      fatty acid), on apoptosis (natural cell death) and cell proliferation (formation of new&#xD;
      cells) in the lining of the colon for patients with a history of colonic polyps.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Colorectal cancer is generally accepted to develop from changes within colonic adenomatous&#xD;
      polyps. More than 90% of new large bowel cancers arise sporadically. The molecular events&#xD;
      leading to the development of colorectal cancer from polyps are characterised by an imbalance&#xD;
      in cell proliferation (formation of new cells) and apoptosis (natural cell death) from&#xD;
      changes in the genes involved in normal colon cells.&#xD;
&#xD;
      Recent work at St George's Hospital Medical School, London, has shown significant beneficial&#xD;
      effects on cell proliferation and apoptosis rates in the lining of the colon in subjects with&#xD;
      a history of colonic adenomas using a highly purified, free-fatty acid form of&#xD;
      eicosapentaenoic acid (EPA).&#xD;
&#xD;
      Comparator(s): 2g EPA per day for 6 months and 1g EPA per day for 6 months will be compared&#xD;
      against placebo for 6 months.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>October 2006</start_date>
  <completion_date type="Actual">June 2008</completion_date>
  <primary_completion_date type="Actual">June 2008</primary_completion_date>
  <phase>Phase 2/Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>To measure levels of apoptosis in the normal colonic mucosa in subjects with a history of colonic adenomas, before and after treatment with EPA 99%.</measure>
    <time_frame>3 months and 6 months</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>To measure levels of cell proliferation in the normal colonic mucosa in subjects with a history of colonic adenomas, before and after treatment with EPA 99%.</measure>
    <time_frame>3 months and 6 months</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>To measure the tissue content of EPA in the colonic mucosa before, during and after treatment with EPA.</measure>
    <time_frame>3 months and 6 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>To determine the safety and tolerability of EPA.</measure>
    <time_frame>3 months and 6 months</time_frame>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">120</enrollment>
  <condition>Adenomatous Polyps</condition>
  <arm_group>
    <arm_group_label>1g EPA per day</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>2g EPA per day</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Eicosapentaenoic Acid (EPA)</intervention_name>
    <description>Either 2 x 500mg EPA capsules in the morning and evening (2g per day EPA) or 1 x 500mg EPA and 1 x placebo in the morning and evening (1g per day EPA)</description>
    <arm_group_label>1g EPA per day</arm_group_label>
    <arm_group_label>2g EPA per day</arm_group_label>
    <other_name>ALFA</other_name>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Endoscopy</intervention_name>
    <description>At baseline, month 3 and month 6.</description>
    <arm_group_label>1g EPA per day</arm_group_label>
    <arm_group_label>2g EPA per day</arm_group_label>
    <arm_group_label>Placebo</arm_group_label>
    <other_name>Colonoscopy</other_name>
    <other_name>Flexible sigmoidoscopy</other_name>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Biopsies taken</intervention_name>
    <description>9 biopsies taken for measurement of apoptosis (3 biopsies), cell proliferation (3 biopsies) and fatty acid levels (3 biopsies) at baseline, month 3 and month 6.</description>
    <arm_group_label>1g EPA per day</arm_group_label>
    <arm_group_label>2g EPA per day</arm_group_label>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Clinical chemistry</intervention_name>
    <description>Full blood count at baseline, month 3 and month 6.</description>
    <arm_group_label>1g EPA per day</arm_group_label>
    <arm_group_label>2g EPA per day</arm_group_label>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Haematology</intervention_name>
    <description>Urea and electrolytes, liver function tests, clotting profile and CRP at baseline, month 3 and month 6.</description>
    <arm_group_label>1g EPA per day</arm_group_label>
    <arm_group_label>2g EPA per day</arm_group_label>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Physical examination</intervention_name>
    <description>Including cardio-respiratory and abdominal examination at baseline, month 3 and month 6.</description>
    <arm_group_label>1g EPA per day</arm_group_label>
    <arm_group_label>2g EPA per day</arm_group_label>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Vital signs</intervention_name>
    <description>Height, weight, heart rate, blood pressure and temperature at baseline, month 3 and month 6.</description>
    <arm_group_label>1g EPA per day</arm_group_label>
    <arm_group_label>2g EPA per day</arm_group_label>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Urine pregnancy test</intervention_name>
    <description>For subjects of child-bearing potential, urine pregnancy test at baseline, month 3 and month 6.</description>
    <arm_group_label>1g EPA per day</arm_group_label>
    <arm_group_label>2g EPA per day</arm_group_label>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Completion of patient diary card</intervention_name>
    <description>Subjects are requested to complete when study medication is taken and in any new or unusual symptoms are experienced on a daily basis for 6 months.</description>
    <arm_group_label>1g EPA per day</arm_group_label>
    <arm_group_label>2g EPA per day</arm_group_label>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Males or females aged over 18&#xD;
&#xD;
          -  Patients of child-bearing potential must demonstrate a negative pregnancy test at&#xD;
             screening, and should use a reliable form of contraception during the trial and for 1&#xD;
             month afterwards, e.g:&#xD;
&#xD;
          -  Oral contraceptive + condom&#xD;
&#xD;
          -  Intra-uterine device (IUD)+ condom&#xD;
&#xD;
          -  Diaphragm with spermicide + condom&#xD;
&#xD;
          -  Male partners of women of child bearing potential should use a reliable form of&#xD;
             contraception during the trial and for 1 month afterwards, e.g:&#xD;
&#xD;
          -  Oral contraceptive + condom&#xD;
&#xD;
          -  Intra-uterine device (IUD)+ condom&#xD;
&#xD;
          -  Diaphragm with spermicide + condom&#xD;
&#xD;
          -  Patients must have a known history of colorectal adenomata and be under clinical&#xD;
             follow-up for these, or be found to have one or more of these at the time of&#xD;
             colonoscopy&#xD;
&#xD;
          -  Patients must have provided written informed consent to participate&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Patients who are allergic to fish&#xD;
&#xD;
          -  Patients who have diabetes mellitus&#xD;
&#xD;
          -  Patients who are pregnant or breast-feeding&#xD;
&#xD;
          -  Patients taking aspirin or other non-steroidal anti-inflammatory drugs on a regular&#xD;
             basis&#xD;
&#xD;
          -  Patients who have aspirin-sensitive asthma&#xD;
&#xD;
          -  Patients suffering from haemorrhagic disorders&#xD;
&#xD;
          -  Patients who are taking warfarin or other anticoagulants&#xD;
&#xD;
          -  Patients who have significant abnormalities on their screening blood tests&#xD;
&#xD;
          -  Patients taking lipid lowering medication&#xD;
&#xD;
          -  Patients with known inflammatory bowel disease (IBD), or previously unknown IBD until&#xD;
             discovered at the time of their colonoscopy&#xD;
&#xD;
          -  Patients with gastrointestinal malabsorptive disease&#xD;
&#xD;
          -  Patients belonging to a known polyposis syndrome (e.g. FAP, HNPCC)&#xD;
&#xD;
          -  Patients with a previous colonic resection for colorectal cancer&#xD;
&#xD;
          -  Patients who are taking other fish-oil supplements (e.g. cod liver oil) who are&#xD;
             unwilling to stop them for the duration of the study&#xD;
&#xD;
          -  Patients who are deemed mentally incompetent, or have a history of anorexia nervosa or&#xD;
             bulimia&#xD;
&#xD;
          -  Patients with a history of alcohol or drug abuse, including laxative abuse&#xD;
&#xD;
          -  Patients considered by their physician unlikely to be able to comply with the&#xD;
             protocol.&#xD;
&#xD;
          -  Patients who have taken part in an experimental drug study in the preceding 2 months.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Nicholas J West, MB BS FRCS</last_name>
    <role>Principal Investigator</role>
    <affiliation>St. George's Hospital Medical School, London</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>S. Orsola Hospital</name>
      <address>
        <city>Bologna</city>
        <zip>40138</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>St. George's Hospital Medical School</name>
      <address>
        <city>London</city>
        <zip>SW17 0RE</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Italy</country>
    <country>United Kingdom</country>
  </location_countries>
  <verification_date>October 2008</verification_date>
  <study_first_submitted>February 7, 2007</study_first_submitted>
  <study_first_submitted_qc>February 7, 2007</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 8, 2007</study_first_posted>
  <last_update_submitted>October 16, 2008</last_update_submitted>
  <last_update_submitted_qc>October 16, 2008</last_update_submitted_qc>
  <last_update_posted type="Estimate">October 17, 2008</last_update_posted>
  <keyword>Eicosapentaenoic acid</keyword>
  <keyword>EPA</keyword>
  <keyword>EPA 99%</keyword>
  <keyword>Fatty acid</keyword>
  <keyword>omega-3</keyword>
  <keyword>apoptosis</keyword>
  <keyword>cell proliferation</keyword>
  <keyword>colonic mucosa</keyword>
  <keyword>polyps</keyword>
  <keyword>adenomatous polyps</keyword>
  <keyword>endoscopy</keyword>
  <keyword>PUFA</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Adenomatous Polyps</mesh_term>
    <mesh_term>Polyps</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

